EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Open Access

Stereotactic Ablative Radiotherapy for T1 to T2 Glottic Larynx Cancer: Mature Results From the Phase 2 GLoTtic Larynx-SABR Trial

David J Sher, Vladimir Avkshtol, Dominic Moon, Dat Vo, Ted Mau, Lesley Childs, Mu-Han Lin, Jeffrey Dubas, Chul Ahn, Baran D Sumer

International Journal of Radiation Oncology*Biology*Physics · 2025

DOI: 10.1016/j.ijrobp.2024.07.2147 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift International Journal of Radiation Oncology*Biology*Physics, 2025. Verfasst von David J Sher und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, Texas. Electronic address: david.sher@utsouthwestern.edu. Hauptthemen laut MEDLINE: Laryngeal Neoplasms, Radiosurgery, Glottis. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, The University of Texas Southwestern Medical Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Traditional radiation therapy for early-stage larynx cancer irradiates the whole larynx over 5.5 to 6 weeks. Phase 1 data suggest that stereotactic ablative radiotherapy (SABR) is a viable strategy to reduce the irradiated volume and compress treatment time. This phase 2 study evaluated the efficacy of gLoTtic larynx-SABR in 5 or 16 fractions. METHODS AND MATERIALS: Eligibility required stage 0 to II squamous cell carcinoma of the glottic larynx. The arytenoid cartilage could not be involved beyond the vocal process, and patients smoking more than one pack per day were excluded. The treatment volume consisted of the gross tumor volume, with a 3 mm margin (5 mm craniocaudal) to create the planning target volume. Patients without active smoking and planning target volume

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Laryngeal NeoplasmsRadiosurgeryGlottisHumansAgedMaleMiddle AgedFemaleAged, 80 and overCarcinoma, Squamous CellDose Fractionation, RadiationNeoplasm StagingTumor BurdenNeoplasm Recurrence, Local

Autor:innen und Institutionen

  • Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, Texas. Electronic address: david.sher@utsouthwestern.edu.
  • Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, Texas.
  • Department of Otolaryngology-Head & Neck Surgery, University of Texas Southwestern Medical Center, Dallas, Texas.
  • Department of Population and Data Sciences, University of Texas Southwestern Medical Center, Dallas, Texas.

Förderung

  • NCI NIH HHS
  • The University of Texas Southwestern Medical Center

Zitieren

APA

Sher, D. J., Avkshtol, V., Moon, D., Vo, D., Mau, T., Childs, L., Lin, M. H., Dubas, J., Ahn, C., & Sumer, B. D. (2025). Stereotactic Ablative Radiotherapy for T1 to T2 Glottic Larynx Cancer: Mature Results From the Phase 2 GLoTtic Larynx-SABR Trial. International Journal of Radiation Oncology*Biology*Physics. https://doi.org/10.1016/j.ijrobp.2024.07.2147

Vancouver

Sher DJ, Avkshtol V, Moon D, Vo D, Mau T, Childs L, et al. Stereotactic Ablative Radiotherapy for T1 to T2 Glottic Larynx Cancer: Mature Results From the Phase 2 GLoTtic Larynx-SABR Trial. International Journal of Radiation Oncology*Biology*Physics. 2025. doi:10.1016/j.ijrobp.2024.07.2147

BibTeX
@article{Sher2025,
  author = {Sher, David J and Avkshtol, Vladimir and Moon, Dominic and Vo, Dat and Mau, Ted and Childs, Lesley and Lin, Mu-Han and Dubas, Jeffrey and Ahn, Chul and Sumer, Baran D},
  title = {Stereotactic Ablative Radiotherapy for T1 to T2 Glottic Larynx Cancer: Mature Results From the Phase 2 GLoTtic Larynx-SABR Trial},
  journal = {International Journal of Radiation Oncology*Biology*Physics},
  year = {2025},
  doi = {10.1016/j.ijrobp.2024.07.2147}
}
Kostenlos starten →